Taysha wins FDA breakthrough tag for lead drug (TSHA:NASDAQ)

Group 1 - Taysha Gene Therapies (NASDAQ:TSHA) experienced a ~39% increase in stock price following the U.S. FDA's granting of Breakthrough Therapy designation for its lead candidate TSHA-102, aimed at treating Rett syndrome, a rare neurodevelopmental disorder [4]